← back to search

Ludo Van Den Bosch

Allen Institute for Brain Science · US
Area of research
Neurology · Genetics
Research interest
Research interests include Amyotrophic Lateral Sclerosis Research, Neurogenetic and Muscular Disorders Research, RNA and protein synthesis mechanisms, and RNA Research and Splicing.
h-index
83
citations
34,231
works
413
NIH funding
primary concept
Biology
email

Recent publications

Human FUS is toxic via association with RNA polymerase II in Drosophila
Cell Death and Disease 2026cited by 0position: lastdoi
TDP-43 seeding induces cytoplasmic aggregation heterogeneity and nuclear loss of function of TDP-43
Neuron 2025cited by 26position: middledoi
Glycerophospholipids in ALS: insights into disease mechanisms and clinical implication
Molecular Neurodegeneration 2025cited by 13position: lastdoi
C9orf72 hexanucleotide repeat expansions impair microglial response in ALS
Nature Neuroscience 2025cited by 8position: middledoi
Altered Lipid Homeostasis in Mutant FUSR521H Astrocytes from HiPSCs
Molecular Neurobiology 2025cited by 2position: middledoi
Phosphodiesterase 4D inhibition improves the functional and molecular outcome in a mouse and human model of Charcot Marie Tooth disease 1 A
Biomedicine & Pharmacotherapy 2025cited by 0position: middledoi
The sense of antisense therapies in ALS
Trends in Molecular Medicine 2024cited by 48position: lastdoi
FUS unveiled in mitochondrial DNA repair and targeted ligase-1 expression rescues repair-defects in FUS-linked motor neuron disease
Nature Communications 2024cited by 37position: middledoi
<i>PMP22</i> duplication dysregulates lipid homeostasis and plasma membrane organization in developing human Schwann cells
Brain 2024cited by 20position: lastdoi
Advances and challenges in modeling inherited peripheral neuropathies using iPSCs
Experimental & Molecular Medicine 2024cited by 19position: middledoi
<i>C21ORF2</i> mutations point towards primary cilia dysfunction in amyotrophic lateral sclerosis
Brain 2024cited by 11position: middledoi
A pathogenic mutation in the ALS/FTD gene VCP induces mitochondrial hypermetabolism by modulating the permeability transition pore
Acta Neuropathologica Communications 2024cited by 9position: lastdoi
PP2A and GSK3 act as modifiers of FUS-ALS by modulating mitochondrial transport
Acta Neuropathologica 2024cited by 9position: lastdoi
A deep phenotyping study in mouse and iPSC models to understand the role of oligodendroglia in optic neuropathy in Wolfram syndrome
Acta Neuropathologica Communications 2024cited by 7position: middledoi
Targeting EGLN2/PHD1 protects motor neurons and normalizes the astrocytic interferon response
Cell Reports 2024cited by 7position: lastdoi
Clioquinol improves catalytic activity of PHGDH and shows antiseizure efficacy in patients
medRxiv 2024cited by 0position: middledoi
Hallmarks of neurodegenerative diseases
Cell 2023cited by 1,592position: middledoi
TDP-43 pathology is associated with increased tau burdens and seeding
Molecular Neurodegeneration 2023cited by 63position: middledoi
FUS-ALS hiPSC-derived astrocytes impair human motor units through both gain-of-toxicity and loss-of-support mechanisms
Molecular Neurodegeneration 2023cited by 60position: lastdoi
A toxic gain-of-function mechanism in C9orf72 ALS impairs the autophagy-lysosome pathway in neurons
Acta Neuropathologica Communications 2023cited by 32position: middledoi
Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD/ALS Summit
Neurology and Therapy 2023cited by 32position: middledoi
Single‐cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma
EMBO Molecular Medicine 2023cited by 22position: middledoi
Antisense, but not sense, repeat expanded RNAs activate PKR/eIF2α-dependent ISR in C9ORF72 FTD/ALS
eLife 2023cited by 20position: middledoi
Why should we care about astrocytes in a motor neuron disease?
Frontiers in Molecular Medicine 2023cited by 19position: lastdoi
Abnormal energy metabolism in ALS: a key player?
Current Opinion in Neurology 2023cited by 18position: lastdoi
Author response: Antisense, but not sense, repeat expanded RNAs activate PKR/eIF2α-dependent ISR in C9ORF72 FTD/ALS
2023cited by 1position: middledoi
Current Methods In ALS Research
Journal of Visualized Experiments 2023cited by 0position: lastdoi
Author Reply to Peer Reviews of Single-cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma
2023cited by 0position: middledoi
FUS Unveiled in Mitochondrial DNA Repair and Targeted Ligase-1 Expression Rescues Repair-Defects in FUS-Linked Neurodegeneration
Research Square 2023cited by 0position: middledoi
Astrocyte-targeted gene delivery of interleukin 2 specifically increases brain-resident regulatory T cell numbers and protects against pathological neuroinflammation
Nature Immunology 2022cited by 209position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Philip Van Damme · Universitair Ziekenhuis Leuven51 papers (2012–2025)Wim Robberecht · KU Leuven21 papers (2012–2019)Wendy Scheveneels · VIB-KU Leuven Center for Brain & Disease Research9 papers (2013–2026)Matthieu Moisse · Allen Institute for Brain Science9 papers (2017–2024)Steven Boeynaems · Children's Cancer Center9 papers (2015–2021)Tijs Vandoorne · VIB-KU Leuven Center for Brain & Disease Research9 papers (2018–2024)Wenting Guo · Hubei Polytechnic University8 papers (2014–2021)Katarina Stoklund Dittlau · University of Southern Denmark8 papers (2019–2024)Jimmy Beckers · KU Leuven8 papers (2021–2024)Dietmar Rudolf Thal · KU Leuven8 papers (2020–2025)Nicole Hersmus · Allen Institute for Brain Science8 papers (2013–2025)Elisabeth Rossaert · Allen Institute for Brain Science8 papers (2017–2022)Laura Fumagalli · University of Antwerp7 papers (2019–2025)Veronick Benoy · KU Leuven7 papers (2012–2021)Elke Bogaert · KU Leuven7 papers (2012–2018)Mieke Timmers · KU Leuven7 papers (2012–2019)Lawrence Van Helleputte · KU Leuven6 papers (2017–2021)Bart Swinnen · Valve (United States)6 papers (2018–2022)Frédéric Rousseau · VIB-KU Leuven Center for Cancer Biology6 papers (2016–2025)Robin Lemmens · KU Leuven6 papers (2012–2019)